SCT520FF
/ Sinocelltech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 05, 2025
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
(clinicaltrials.gov)
- P1/2 | N=82 | Recruiting | Sponsor: Sinocelltech Ltd. | Not yet recruiting ➔ Recruiting | N=15 ➔ 82
Enrollment change • Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 1
Of
1
Go to page
1